Medvarsity Logo
Thumbnail for An Update on Diagnosis & Management of Hypertrophic Cardiomyopathy

CASE DISCUSSION

An Update on Diagnosis & Management of Hypertrophic Cardiomyopathy

India flagPresented India by Dr. Saravanan Palaniappan

Views

50

Case Description

Hypertrophic cardiomyopathy (HCM) is a complex cardiac condition that requires timely diagnosis, risk assessment, and individualised management. This session will cover contemporary diagnostic approaches, including echocardiography, cardiac MRI, and genetic evaluation, along with strategies for...

Case Summary

  • Hypertrophic cardiomyopathy is the most prevalent monogenic inherited cardiovascular disorder, transmitted primarily in an autosomal dominant pattern with incomplete, age-dependent penetrance. It is predominantly driven by pathogenic variants in sarcomeric genes, most commonly MYBPC3 and MYH7, while phenotypic mimics such as Fabry disease, Danon disease, and transthyretin cardiac amyloidosis comprise five to ten percent of cases. Pathophysiologically, hyperdynamic actin-myosin cross-bridge cycling and intracellular calcium dysregulation lead to myocyte disarray, interstitial fibrosis, diastolic dysfunction, and dynamic left ventricular outflow tract obstruction caused by asymmetric septal hypertrophy coupled with systolic anterior motion of the anterior mitral leaflet.

Speaker Profile

Dr. Saravanan Palaniappan

Dr. Saravanan Palaniappan

Medical Director and HOD, Cardiovascular Sciences, East Point Medical College and Hospital, Bangalore
Dr. Saravanan Palaniappan is a highly accomplished Senior Interventional Cardiologist, Electrophysiologist, and Heart Transplant Physician with over two decades of clinical and leadership experience across India and the UK. He currently serves as the Head of the Institute of Cardiovascular Sciences and Medical Director – Superspecialty Services at East Point Medical College Hospital, Bengaluru, and is also the Director of Advanced Cardiac Care (ACC), Vellore. Prior to this, he held key leadership roles including Medical Director and HOD of Cardiovascular Sciences at Ponjesly Super Speciality Hospital, where he spearheaded efforts to bring high-quality, affordable cardiac care to underserved Tier-2 and Tier-3 regions in Tamil Nadu. His extensive global experience includes tenures at renowned institutions such as Fortis Hospital (Chennai), Bangalore Baptist Hospital, MIOT International, and leading NHS Trusts in the UK including Liverpool Heart and Chest Hospital, Wythenshawe Hospital, and Royal Brompton and Harefield Hospitals. Dr. Saravanan Palaniappan brings deep expertise in clinical trials, electrophysiology, heart failure management, and cardiac interventions, with a strong commitment to teaching, research, and healthcare equity.

Disclosures

Assimilate by Medvarsity requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity have been reviewed and mitigated. Others involved in the planning of this activity have no relevant financial relationships.